LU92902I2 - GARDASIL-9 / PRODUCT NAME: PROTEIN HPV 45 L1 - Google Patents

GARDASIL-9 / PRODUCT NAME: PROTEIN HPV 45 L1 Download PDF

Info

Publication number
LU92902I2
LU92902I2 LU92902C LU92902C LU92902I2 LU 92902 I2 LU92902 I2 LU 92902I2 LU 92902 C LU92902 C LU 92902C LU 92902 C LU92902 C LU 92902C LU 92902 I2 LU92902 I2 LU 92902I2
Authority
LU
Luxembourg
Prior art keywords
gardasil
product name
protein hpv
hpv
protein
Prior art date
Application number
LU92902C
Other languages
French (fr)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of LU92902I2 publication Critical patent/LU92902I2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
LU92902C 2003-09-29 2015-12-08 GARDASIL-9 / PRODUCT NAME: PROTEIN HPV 45 L1 LU92902I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Publications (1)

Publication Number Publication Date
LU92902I2 true LU92902I2 (en) 2016-03-08

Family

ID=34421558

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92902C LU92902I2 (en) 2003-09-29 2015-12-08 GARDASIL-9 / PRODUCT NAME: PROTEIN HPV 45 L1

Country Status (33)

Country Link
US (2) US7250170B2 (en)
EP (1) EP1673106B1 (en)
JP (4) JP5451960B2 (en)
KR (1) KR101165278B1 (en)
CN (1) CN1859923B (en)
AR (2) AR045804A1 (en)
AT (1) ATE435029T1 (en)
AU (1) AU2004277934B2 (en)
BE (1) BE2015C072I2 (en)
BR (1) BRPI0414845B8 (en)
CA (1) CA2539168C (en)
CY (2) CY1110525T1 (en)
DE (1) DE602004021828D1 (en)
DK (1) DK1673106T3 (en)
ES (1) ES2327530T3 (en)
FR (1) FR15C0083I2 (en)
HU (1) HUS1500063I1 (en)
IL (1) IL174458A (en)
IS (1) IS2694B (en)
LT (2) LTPA2015049I1 (en)
LU (1) LU92902I2 (en)
MX (1) MXPA06003457A (en)
MY (1) MY140664A (en)
NL (1) NL300776I2 (en)
NO (3) NO339932B1 (en)
NZ (1) NZ545834A (en)
PL (1) PL1673106T3 (en)
PT (1) PT1673106E (en)
RU (1) RU2360001C2 (en)
SI (1) SI1673106T1 (en)
TW (1) TWI350853B (en)
WO (1) WO2005032586A1 (en)
ZA (1) ZA200601961B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
EP1730175B1 (en) 2004-03-24 2010-04-28 Merck Sharp & Dohme Corp. Optimized expression of hpv 52 l1 in yeast
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EP1877086A2 (en) * 2005-04-26 2008-01-16 GlaxoSmithKline Biologicals SA Vaccine
EP2059262B1 (en) * 2006-08-28 2013-08-21 Sungkyunkwan University Foundation for Corporate Collaboration A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
EP2479187A1 (en) 2007-11-23 2012-07-25 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
US9566323B2 (en) 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
JP6153866B2 (en) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． Rapid hybrid capture assay and associated strategically cleaved probe
BR112013032338B1 (en) 2011-06-15 2021-04-20 Posvax Co., Ltd method to improve production yield for human papillomavirus l1 protein
US20140127260A1 (en) 2011-06-24 2014-05-08 Ramesh V. Chintala Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CN103215302B (en) * 2012-01-21 2019-01-15 北京安百胜生物科技有限公司 Method for producing HPV18 L1 protein using the Hansenula yeast expression system
CN108624614A (en) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 The method for generating HPV11 L1 albumen with expressed by Hansenula yeast system
CN110423774A (en) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 The method for generating HPV58 L1 albumen with expressed by Hansenula yeast system
CN110484554B (en) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 Method for producing HPV52L1 protein by Hansenula polymorpha expression system
CN110295190A (en) * 2013-05-17 2019-10-01 北京安百胜生物科技有限公司 The method for generating HPV45 L1 albumen with expressed by Hansenula yeast system
CN112280792B (en) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 Human papillomavirus gene, and vector, strain, and expression method
US9782470B2 (en) 2013-10-16 2017-10-10 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106282278B (en) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 A kind of fermentation method of human papillomavirus L1 protein
CN106701798B (en) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 Type 45 recombinant human papillomavirus virus-like particle and preparation method thereof
CN109750050B (en) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 Expression of Recombinant Human Papillomavirus Subtype 45 Protein
CN115103687A (en) 2020-02-14 2022-09-23 默沙东有限公司 HPV vaccine
CN112680462B (en) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 Human papilloma virus 35/HPV 35 type L1/L2 and preparation and application thereof
CN113073105B (en) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 Polynucleotide sequence for expressing HPV56L1, expression vector, host cell and application thereof
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
TW202315602A (en) 2021-08-19 2023-04-16 美商默沙東有限責任公司 Novel thermostable lipid nanoparticle and methods of use thereof
AR132886A1 (en) 2023-06-09 2025-08-06 Merck Sharp & Dohme Llc Adjuvant compositions in nanoemulsion for vaccines against human papillomavirus

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ336696A3 (en) * 1994-05-16 1997-07-16 Merck & Co Inc Isolated and purified proteins of papillomavirus and process for preparing thereof
AR004464A1 (en) * 1994-11-14 1998-12-16 Merck Sharp & Dohme A METHOD FOR PRODUCING A PAPILOMAVIRUS CAPSIDE PROTEIN
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
JP2001512308A (en) 1997-02-07 2001-08-21 メルク エンド カンパニー インコーポレーテッド Synthetic HIV GAG gene
JP3366339B2 (en) * 1997-05-27 2003-01-14 ハニル シンセティック ファイバー カンパニー リミテッド Method for producing recombined protein from Saccharomyces cerevisiae using a highly efficient expression vector
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
SK2232001A3 (en) * 1998-08-14 2001-08-06 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
WO2000009157A1 (en) * 1998-08-14 2000-02-24 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
JP2002535965A (en) * 1998-12-23 2002-10-29 メルク エンド カムパニー インコーポレーテッド Neutralization assay using human papillomavirus virus-like particles
DE60016765T2 (en) * 1999-08-25 2005-11-24 Merck & Co., Inc. SYNTHETIC PAPILLOMA GENES WHICH ARE OPTIMIZED FOR EXPRESSION IN HUMAN CELLS
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
BR0112637A (en) 2000-07-21 2003-06-10 Glaxo Group Ltd Codon-optimized Papilloma Virus Sequences
WO2003068804A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2519112C (en) 2003-03-24 2012-09-11 Merck & Co., Inc. Optimized expression of hpv 31 l1 in yeast

Also Published As

Publication number Publication date
US7482015B2 (en) 2009-01-27
NO20061876L (en) 2006-04-28
IS8362A (en) 2006-03-20
AR045804A1 (en) 2005-11-16
AU2004277934A1 (en) 2005-04-14
BRPI0414845B1 (en) 2020-10-13
CA2539168C (en) 2011-05-31
PL1673106T3 (en) 2009-12-31
JP2014221052A (en) 2014-11-27
JP2007507207A (en) 2007-03-29
KR20070029628A (en) 2007-03-14
HUS1500063I1 (en) 2016-02-29
RU2360001C2 (en) 2009-06-27
SI1673106T1 (en) 2009-12-31
NO339932B1 (en) 2017-02-20
JP2016136947A (en) 2016-08-04
IS2694B (en) 2010-11-15
CY2015050I2 (en) 2016-06-22
TW200521233A (en) 2005-07-01
FR15C0083I2 (en) 2016-11-25
TWI350853B (en) 2011-10-21
KR101165278B1 (en) 2012-07-23
NO2022051I1 (en) 2022-11-30
JP5451960B2 (en) 2014-03-26
WO2005032586A1 (en) 2005-04-14
LTC1673106I2 (en) 2017-05-10
NZ545834A (en) 2009-02-28
US20060240040A1 (en) 2006-10-26
ATE435029T1 (en) 2009-07-15
FR15C0083I1 (en) 2016-08-01
AU2004277934B2 (en) 2009-09-17
AR077396A2 (en) 2011-08-24
JP2011152137A (en) 2011-08-11
CA2539168A1 (en) 2005-04-14
EP1673106B1 (en) 2009-07-01
LTPA2015049I1 (en) 2016-01-11
MY140664A (en) 2010-01-15
CN1859923A (en) 2006-11-08
CN1859923B (en) 2012-09-05
DK1673106T3 (en) 2009-11-09
BE2015C072I2 (en) 2023-12-14
EP1673106A1 (en) 2006-06-28
ES2327530T3 (en) 2009-10-30
IL174458A (en) 2014-06-30
CY2015050I1 (en) 2016-06-22
NO2017012I1 (en) 2017-04-05
ZA200601961B (en) 2007-05-30
IL174458A0 (en) 2006-08-01
NL300776I1 (en) 2015-12-29
PT1673106E (en) 2009-09-22
BRPI0414845A (en) 2006-11-21
NL300776I2 (en) 2015-12-29
RU2006114701A (en) 2007-11-10
CY1110525T1 (en) 2015-04-29
US20080138361A1 (en) 2008-06-12
BRPI0414845B8 (en) 2021-06-15
MXPA06003457A (en) 2006-06-05
US7250170B2 (en) 2007-07-31
DE602004021828D1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
LU92902I2 (en) GARDASIL-9 / PRODUCT NAME: PROTEIN HPV 45 L1
LU92903I2 (en) GARDASIL-9 / PRODUCT NAME: PROTEIN HPV 52 L1
LU92901I2 (en) GARDASIL-9 / PRODUCT NAME: HPV58L1 PROTEIN
FR2838048B1 (en) DENTAL / DERETICULABLE DENTAL PRODUCT
DE602004012052D1 (en) Acoustically coupled product label
EP1970753A4 (en) IDENTIFICATION PRODUCT
DE602004029184D1 (en) DISPOSABLE SCRUBBING PRODUCT
ATE555190T1 (en) DISPOSABLE CLEANING PRODUCT
FR2819718B1 (en) COSMETIC PRODUCT
SE0301552L (en) New product
FR2877842B1 (en) ANTI-TRANSPIRANT AEROSOL PRODUCT
FR2837844B1 (en) NEW REINFORCEMENT PRODUCT
SE0300002L (en) New product
GB0315248D0 (en) HCV regulated protein expression
EP1637883A4 (en) IMUNOCHROMATOGRAPHIC PROCESS
EP1384767A4 (en) LAMINATE PRODUCT
DK1691751T3 (en) hygiene Product
FR2861365B1 (en) PROCESS FOR PACKAGING SOFT SOFT INSULATING MATERIAL
FI20031105L (en) Hygiene product
FR2850973B1 (en) BI-COMPONENT PRODUCT
EP1691645A4 (en) APPARATUS FOR DISSIMINATING A PRODUCT
FR2856994B1 (en) PRODUCT DISTRIBUTION ASSEMBLY
FR2828632B1 (en) VIENNOISERIE PRODUCT
FI5970U1 (en) product packaging
UA8093S (en) LABEL FOR DAIRY PRODUCTS